217 Users Online
Epilepsy Treatment Market
The global epilepsy treatment market expanded at a 7.3% CAGR from 2012 to 2022 to reach US$ 6.5 billion in 2022. The market is forecasted to expand at a CAGR of 7.7% and climb to US$ 14.7 billion by the end of 2033.
Epilepsy is a type of neurological disorder characterized by recurrent seizures, caused due to abnormal electrical activities in the brain. Seizures can manifest in many different ways, from convulsions and loss of consciousness to subtle changes in behavior, perception, or sensation. Epilepsy can develop at any age but is most commonly diagnosed in children and older adults.
Prevalence of epilepsy has been increasing globally in recent years. One of the main reasons is the expanding aging population. Epilepsy is more common in older adults, and as the population ages, the number of people with epilepsy is expected to rise. Advances in medical technology have made it easier to diagnose epilepsy, and greater awareness of the condition has led to more people seeking medical attention for seizures.
Incidence of traumatic brain injury (TBI) has been increasing due to various factors, including an increase in road traffic accidents, falls, and sports-related injuries. The increasing incidence of risk factors such as TBI, stroke, and brain tumors highlights the need for greater efforts to prevent these conditions and to provide appropriate treatment and support for people who develop epilepsy as a result.
Epilepsy Treatment Market Size (2023)
US$ 7 Billion
Projected Market Value (2033)
US$ 14.7 Billion
Global Market Growth Rate (2023 to 2033)
Market Share of Top 5 Countries
“Increasing Worldwide Prevalence of Stroke and Drug-resistant Epilepsy”
Each person's response to medication can vary due to factors such as genetic differences, metabolism, or the specific characteristics of their epilepsy. What works for one person may not be as effective for another. It requires a trial-and-error process to find the most suitable medication and dosage for each individual.
In some cases, individuals may develop a tolerance to antiepileptic drugs (AEDs), reducing the effectiveness of the medication. Higher doses may be required to achieve the same level of seizure control.
Implantation of intracranial electrodes that make recordings of areas suspected of causing seizures can help localize seizures in situations where non-invasive testing is inadequate. Recent developments allow long-term intracranial recordings in ambulatory settings. Implantable neurostimulators are a promising tool for palliative options and make a major shift in epileptology and neuroscience research.
Stroke is another significant risk factor for epilepsy, particularly in older adults. The incidence of stroke has been increasing globally. Stroke can cause damage to the brain leading to the development of epilepsy. The risk factors for developing epilepsy after a stroke include the severity and location of the stroke, hemorrhagic stroke (compared to ischemic stroke), older age, and the presence of other underlying risk factors such as prior history of seizures, structural brain abnormalities, or previous strokes.
Increasing prevalence of stroke & drug-resistant epilepsy is expected to drive the demand for advanced epilepsy treatment over the forecasted period.
“Product Recalls and Patients’ Inability to Afford Branded Medications”
Persistent quality problems with medical devices and associated recalls pose a potential health risk to patients and staff who use these devices. The company or manufacturer bears the cost of replacing and repairing defective products or reimbursing affected consumers, which can affect its financial investment. Recalls can damage a company's reputation and can lead to multibillion-dollar losses.
Another factor likely to hamper the growth of the epilepsy treatment market is the patient’s struggle to afford branded medication. The anti-seizure medications had been in second place in terms of cost among the prescriptions that neurologists typically prescribe. Exorbitant prices of drugs used to treat neurological disorders represent a restraining factor that could hinder market growth.
Prices of branded drugs used to treat epilepsy have risen steadily since 2010, largely due to a surge in prescriptions for the drug lacosamide and a sharp rise in the price per tablet, with branded drugs costing 10 times as much as their generic counterparts.
The most interesting fact is that prices for branded drugs increased after 2010, as generic drugs from leading players such as Keppra became more expensive per tablet and a new brand-only drug called lacosamide, marketed under the name Vimpat, entered the epilepsy treatment market, wiping out the earlier cost gains.
Frequent product recalls may hinder manufacturer participation, which may limit product availability and development of new products and increase patients’ struggle to afford branded medications. These factors are expected to affect market growth in the coming years.
What Makes the U.S. a Lucrative Market for Providers of Epilepsy Treatment?
“Increased Awareness of Neurological Disorders and Availability Efficient Diagnostic Procedures for Epilepsy”
The U.S. accounted for 29.7% share of the global market in 2022.
The U.S. market is growing mainly due to increased awareness and diagnosis of epilepsy in the US, leading to better identification and treatment of neurological conditions. This is due to greater education and awareness campaigns, as well as improvements in diagnostic tools and healthcare access.
What is the Demand Outlook for Epilepsy Treatment in China?
“High Prevalence of Brain Disorders and Focus on Clinical Research Activities”
China held 8.5% share of the global market in 2022.
China's increasing aging population and rising healthcare costs, together with the rising prevalence of epilepsy, are the key factors driving market growth in this country. Deficiency in healthcare delivery and social discrimination from cultural beliefs about epilepsy are a few factors creating a vast gap in epilepsy treatment in China.
At present, more than 20 anti-seizure medications and various non-pharmacological options are available to treat epilepsy in China. Ongoing clinical research activities to better understand the epidemiology of epilepsy and develop new therapeutics are likely to drive the Chinese market going forward.
How is Demand for Epilepsy Treatment Shaping Up in Germany?
“Advancements in Medical Technology and Increased Awareness of Neurological Conditions”
Germany accounted for 6.4% share of the global market in 2022.
In Germany, the prevalence of epilepsy is high resulting in higher healthcare costs. Diagnosis of epilepsy has become easier in recent years due to advances in medical technology and increased awareness of the conditions. A better understanding of epileptic conditions among healthcare professionals and the availability of more accurate diagnostic tools have led to higher detection rates, driving the epilepsy treatment market in Germany.
Which Treatment Type Accounts for a Leading Market Share?
“High Demand for Drugs and Surgery Due to Their Immediate and Effective Results”
The treatment type segment held 72.8% share of the global market in 2022.
Drugs and surgery are often preferred over treating epilepsy with medical devices because they can provide more immediate and effective results in controlling seizures and improving the quality of life for people with epilepsy. For some people with epilepsy who do not respond to medication or who have seizures that originate from a specific area of the brain, epilepsy surgeries can be a highly effective treatment option.
Which Seizure Type Accounts for High Demand for Epilepsy Treatment?
“Increased Demand for Treatment for Focal Seizures Due to Their Higher Prevalence Compared to Generalized Seizures”
The focal seizures segment held 61.1% share of the global market in 2022.
Focal seizures, also known as partial seizures, account for a higher number of cases compared to generalized seizures.
The market for epilepsy treatment has a fair amount of competition. Key players in the market are also striving to expand their presence in emerging markets with new partnerships, mergers, and acquisitions and focusing on launching new technologically advanced products.
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the epilepsy treatment market, which are available in the full report.
2023 to 2033
Historical Data Available for
2012 to 2022
US$ Billion for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Covered
Customization & Pricing
Available upon Request
Diagnosis & Treatment Type:
The global epilepsy treatment market was valued at US$ 6.5 billion in 2022.
Demand for epilepsy treatment increased at 7.3% CAGR from 2012 to 2022.
The U.S. accounted for 29.7% share of the global market in 2022.
China accounted for 8.5% share of the global market in 2022.
Focal seizures held 61.1% share of the global market in 2022.
The global market is set to reach a valuation of US$ 14.7 billion by the end of 2033.
Demand for epilepsy treatment is predicted to rise at a CAGR of 7.7% through 2033.
The U.S., China, Japan, Germany, and India collectively account for 56.7% market share.